Biopharmaceutical company Gilead Sciences has issued a voluntary recall of one lot of Vistide (cidofovir injection) at user level due to incidence of particulate matter in few vials.
The recalled lot of the product was distributed to wholesalers, hospital and retail pharmacies in the US, Canada and Europe.
The hypertonic, clear and colorless solution that has been supplied in clear glass vials is specified only for intravenous infusion.
Vistide is indicated to treat cytomegalovirus (CMV) retinitis in acquired immunodeficiency syndrome (AIDS) patients.
Cidofovir works by suppressing the CMV replication by selective inhibition of viral DNA synthesis.
Source:
http://drugdelivery.pharmaceutical-business-review.com/news/gilead-voluntarily-recalls-one-lot-of-vistide-180213
